Literature DB >> 22738072

The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

M Ndonwi, T J Girard, G J Broze.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22738072      PMCID： PMC3462013          DOI： 10.1111/j.1538-7836.2012.04834.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  9 in total

1.  Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein.

Authors:  T J Girard; L A Warren; W F Novotny; B E Bejcek; J P Miletich; G J Broze
Journal:  Thromb Res       Date:  1989-07-01       Impact factor: 3.944

2.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

Authors:  R Wesselschmidt; K Likert; T Girard; T C Wun; G J Broze
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

3.  Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.

Authors:  R Wesselschmidt; K Likert; Z Huang; L MacPhail; G J Broze
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

4.  Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.

Authors:  T Kokawa; K Enjyoji; K Kumeda; Y Kamikubo; M Harada-Shiba; H Koh; M Tsushima; A Yamamoto; H Kato
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-06       Impact factor: 8.311

5.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

6.  Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).

Authors:  P Lesnik; A Vonica; M Guérin; M Moreau; M J Chapman
Journal:  Arterioscler Thromb       Date:  1993-07

7.  Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli.

Authors:  J A Diaz-Collier; M O Palmier; K K Kretzmer; B F Bishop; R G Combs; M G Obukowicz; R B Frazier; G S Bild; W D Joy; S R Hill
Journal:  Thromb Haemost       Date:  1994-03       Impact factor: 5.249

8.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.

Authors:  G J Broze; L A Warren; W F Novotny; D A Higuchi; J J Girard; J P Miletich
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

9.  Heterogeneity of plasma tissue factor pathway inhibitor.

Authors:  G J Broze; G W Lange; K L Duffin; L MacPhail
Journal:  Blood Coagul Fibrinolysis       Date:  1994-08       Impact factor: 1.276
  9 in total
  15 in total

1.  Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.

Authors:  George J Broze; Thomas J Girard
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

2.  Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Authors:  Matthew W Bunce; Mettine H A Bos; Sriram Krishnaswamy; Rodney M Camire
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

3.  Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Authors:  Kanagasabai Vadivel; Sathya-Moorthy Ponnuraj; Yogesh Kumar; Anne K Zaiss; Matthew W Bunce; Rodney M Camire; Ling Wu; Denis Evseenko; Harvey R Herschman; Madhu S Bajaj; S Paul Bajaj
Journal:  J Biol Chem       Date:  2014-09-28       Impact factor: 5.157

4.  Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: Structural insights from molecular modeling studies.

Authors:  Kanagasabai Vadivel; Yogesh Kumar; Matthew W Bunce; Rodney M Camire; Madhu S Bajaj; S Paul Bajaj
Journal:  Int Biol Rev       Date:  2017-05

Review 5.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

6.  Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.

Authors:  Lisa M Vincent; Sinh Tran; Ruzica Livaja; Tracy A Bensend; Dianna M Milewicz; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

7.  Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.

Authors:  Paul E R Ellery; Ida Hilden; Peter Thyregod; Nicholas D Martinez; Susan A Maroney; Joan C Gill; Alan E Mast
Journal:  Haemophilia       Date:  2019-10-14       Impact factor: 4.287

8.  TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.

Authors:  Jeremy P Wood; Helle H Petersen; Bingke Yu; Xiaoai Wu; Ida Hilden; Alan E Mast
Journal:  Blood Adv       Date:  2017-12-26

9.  Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.

Authors:  Jeremy P Wood; Lisa M Baumann Kreuziger; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood Adv       Date:  2017-02-14

10.  Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.

Authors:  Jeremy P Wood; Matthew W Bunce; Susan A Maroney; Paula B Tracy; Rodney M Camire; Alan E Mast
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.